Jaguar Health Inc
JAGX
Company Profile
Business description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Contact
200 Pine Street
Suite 400
San FranciscoCA94104
USAT: +1 415 371-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.50 | 2.90 | 0.03% |
| CAC 40 | 8,112.02 | 8.44 | 0.10% |
| DAX 40 | 24,351.12 | 11.06 | 0.05% |
| Dow JONES (US) | 48,461.93 | 249.04 | -0.51% |
| FTSE 100 | 9,866.53 | 4.15 | -0.04% |
| HKSE | 25,729.86 | 94.63 | 0.37% |
| NASDAQ | 23,474.35 | 118.75 | -0.50% |
| Nikkei 225 | 50,422.04 | 104.88 | -0.21% |
| NZX 50 Index | 13,537.47 | 11.48 | 0.08% |
| S&P 500 | 6,905.74 | 24.20 | -0.35% |
| S&P/ASX 200 | 8,722.90 | 1.70 | 0.02% |
| SSE Composite Index | 3,961.74 | 3.54 | -0.09% |